Dopamine– tag –
-
iPS-Derived Dopaminergic Neuron Transplants Show Early Safety and Efficacy, Offering New Hope for Parkinson’s Disease Treatment
NeurologyLive USA Overview Stem cell therapy involving the transplantation of iPS cell-derived dopaminergic neurons into the brain is emerging as a promising approach for Parkinson's disease (PD) treatment. Initial clinical trial results... -
Stem Cell Therapies for Parkinson’s Disease Advance to Clinical Stages: BlueRock’s Phase 3 and Japanese iPSC Program Lead the Way
NeurologyLive USA Overview Stem cell therapies for Parkinson's Disease, particularly dopamine cell replacement trials, are making significant strides into advanced clinical stages. BlueRock Therapeutics' embryonic stem cell (ESC)-derived... -
BlueRock Therapeutics Initiates Patient Enrollment for Parkinson’s Disease iPSC-Derived Cell Therapy exPDite-2 Phase 3 Trial; Long-Term Follow-Up Data Imminent
Neurology Live USA Overview BlueRock Therapeutics has initiated patient enrollment for its Phase 3 exPDite-2 clinical trial, transplanting iPSC-derived dopaminergic neurons in Parkinson's disease patients. The trial will involve approxim... -
Japan: AMCHEPRY® for Parkinson’s (~$350,600) and RiHEART® for Severe Heart Failure (~$63,500+) iPSC Cell Therapies Show Positive Early Clinical Results in 7 Patients
Reddit (r/stemcells) Japan Overview Early clinical trials for Japan-originated iPSC cell therapies, AMCHEPRY® for Parkinson's disease and RiHEART® for severe ischemic heart failure, have shown positive results in a total of seven patient... -
Pioneering Pluripotency: Japan Approves World’s First iPSC-Derived Therapies for Heart Failure and Parkinson’s
再生医療 みなとみらい麻の葉クリニック Japan Overview In a historic global first, Japan's Ministry of Health, Labour and Welfare has granted conditional and time-limited approval to two induced pluripotent stem cell (iPSC)-derived regener... -
iPSC Clinical Trials Deliver Breakthroughs: Parkinson’s, Heart Failure, Cancer Immunotherapies Show Promising Results
Americord Registry USA Overview Induced pluripotent stem cell (iPSC) research is rapidly transforming medicine, with multiple clinical trials reporting significant progress across diverse disease areas. A Kyoto University Hospital trial ... -
XellSmart Initiates Phase II Trial for iPSC-Based Parkinson’s Therapy Following Encouraging Phase I Results
The Regen Report USA Overview XellSmart has advanced its iPSC-derived cellular therapy for Parkinson's disease into Phase II clinical trials, driven by positive safety and preliminary efficacy data from its Phase I study. This critical p... -
Japan Approves Pricing for World’s First iPSC-Derived Product, Amchepry, Signaling New Era for Regenerative Medicine
薬事日報 Japan Overview Japan's Central Social Insurance Medical Council has approved the official drug pricing for three new regenerative medicine products, including Sumitomo Pharma's iPSC-derived dopamine neural progenitor cells, Amch...
12